bi 764532
boehringer ingelheim
['nct04429087']
additionally, promising efficacy signals were reported namely response rates and disease control rates in the phase 1 clinical trial (nct04429087) data that were presented #asco23 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.